EFG vs IVIG in TAMG

Clinical trial NCT07231523 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07231523
Sponsor: Shanghai Zhongshan Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Efgartigimod Intravenous Immunoglobulin Myasthenia Gravis Associated With Thymoma

Start date: 2025-12-01
Primary completion: 2027-06-01
Enrollment: 64

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.